Limits...
Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus

Mean 24-hour, diurnal, and nocturnal intraocular pressure in a cohort of primary open-angle glaucoma patients treated with travoprost monotherapy and followed-up for 5 years.Note: Reprinted with permission from Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540.49
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401333&req=5

f2-opth-9-633: Mean 24-hour, diurnal, and nocturnal intraocular pressure in a cohort of primary open-angle glaucoma patients treated with travoprost monotherapy and followed-up for 5 years.Note: Reprinted with permission from Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540.49

Mentions: Not many studies investigated 24-hour long-term persistency of travoprost hypotensive efficacy. In a recent study by Riva et al, travoprost 0.004% given as monotherapy in a cohort of 36 previously untreated POAG patients, induced a quite uniform 24-hour IOP reduction during the 5-year follow-up of the study (range of 24-hour IOP reduction: 27.8%–28.6%, Figure 2).49 Interestingly, although mean nocturnal IOP reduction with travoprost was somewhat lower than mean daytime IOP reduction, there was no significant difference between nighttime and daytime efficacy (P>0.05).


Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Mean 24-hour, diurnal, and nocturnal intraocular pressure in a cohort of primary open-angle glaucoma patients treated with travoprost monotherapy and followed-up for 5 years.Note: Reprinted with permission from Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540.49
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401333&req=5

f2-opth-9-633: Mean 24-hour, diurnal, and nocturnal intraocular pressure in a cohort of primary open-angle glaucoma patients treated with travoprost monotherapy and followed-up for 5 years.Note: Reprinted with permission from Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540.49
Mentions: Not many studies investigated 24-hour long-term persistency of travoprost hypotensive efficacy. In a recent study by Riva et al, travoprost 0.004% given as monotherapy in a cohort of 36 previously untreated POAG patients, induced a quite uniform 24-hour IOP reduction during the 5-year follow-up of the study (range of 24-hour IOP reduction: 27.8%–28.6%, Figure 2).49 Interestingly, although mean nocturnal IOP reduction with travoprost was somewhat lower than mean daytime IOP reduction, there was no significant difference between nighttime and daytime efficacy (P>0.05).

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus